In previous study, we prepared a TIMP2-based recombinant protein and its enediyne-integrated analog, and subsequently, demonstrated their antitumor efficacy against human esophageal carcinoma xenografts in athymice mice. Here, TIMP2 is linked to carcinoma of esophagus.